3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Unknown
1
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Neoplasms
3
Head and Neck Neoplasms
3
Pain
2
Lung Neoplasms
2
Colorectal Neoplasms
2
Cancer Pain
2
Wounds and Injuries
1
Uterine Cervical Neoplasms
1
Thyroid Neoplasms
1
Recurrent Laryngeal Nerve Injuries
1
Recurrence
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Pleural Effusion, Malignant
1
Pilonidal Sinus
1
Pain, Postoperative
1
Pain, Intractable
1
Oropharyngeal Neoplasms
1
Neoplasm Metastasis
1
Liver Neoplasms
1
Intracranial Aneurysm
1
Ileus
1
Diverticulosis, Colonic
1
Diverticulitis, Colonic
1
Disease Progression
1
Constipation
1
Colonic Neoplasms
1
Breast Neoplasms
1
Agnosia
1
Accessory Nerve Injuries
1
Interventions
Cyclophosphamide
17
fludarabine
13
Dexamethasone
12
Cisplatin
12
Rituximab
10
Gemcitabine
9
Paclitaxel
8
Bendamustine Hydrochloride
8
Lenalidomide
7
Decitabine
7
Cytarabine
7
Carboplatin
7
fludarabine phosphate
6
N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide
6
Etoposide
6
Bortezomib
6
Radiotherapy
5
Injections
5
Azacitidine
5
camrelizumab
4
apatinib
4
Valproic Acid
4
Thalidomide
4
Procarbazine
4
Oxaliplatin
4
Drug Therapy
4
Bevacizumab
4
Antilymphocyte Serum
4
venetoclax
3
pomalidomide
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Unknown
×
Recurrence
×
Lidocaine
×
Clear all
NCT05250791
2023-06-09
FLICOR
Imperial College London
Phase NA
Unknown
50 enrolled